7MW 4911
Alternative Names: 7MW-4911Latest Information Update: 31 Mar 2025
At a glance
- Originator Mabwell (Shanghai) Bioscience
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 24 Feb 2025 Mabwell (Shanghai) Bioscience files for patent protection for the molecular structure of 7MW 4911, before February 2025 (Mabwell (Shanghai) Bioscience pipeline, February 2025)
- 24 Feb 2025 Mabwell (Shanghai) Bioscience has patent protection for 7MW 4911, before February 2025 (Shanghai) Bioscience pipeline, February 2025)
- 24 Feb 2025 Preclinical trials in Solid tumours in China (Parenteral), before February 2025 (Mabwell (Shanghai) Bioscience pipeline, February 2025)